Equities

Repligen Corp

Repligen Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)142.58
  • Today's Change0.82 / 0.58%
  • Shares traded556.88k
  • 1 Year change-11.00%
  • Beta0.9507
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.

  • Revenue in USD (TTM)622.64m
  • Net income in USD-17.13m
  • Incorporated1981
  • Employees1.78k
  • Location
    Repligen CorpBUILDING 1, SUITE 100, 41 SEYON STREETWALTHAM 02453United StatesUSA
  • Phone+1 (781) 449-9560
  • Fax+1 (302) 655-5049
  • Websitehttps://www.repligen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RGEN:NSQ since
announced
Transaction
value
Maravai LifeSciences Holdings IncRumoured16 Aug 202416 Aug 2024Rumoured-12.32%--
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Integer Holdings Corp1.68bn114.44m4.56bn10.50k41.892.8120.602.713.243.2247.8748.330.55944.935.14160,023.803.813.284.103.5327.0626.946.816.402.094.110.40280.0016.035.6238.719.3321.71--
Procept Biorobotics Corp199.84m-100.06m5.11bn626.00--20.42--25.55-1.95-1.953.894.630.50261.833.86319,238.00-25.16---28.58--57.39---50.07--5.07--0.1758--81.55---21.51------
Inspire Medical Systems Inc755.59m33.05m5.58bn1.01k171.118.01146.817.381.091.0925.1523.251.052.469.37747,372.904.60-11.275.12-12.6084.7784.474.37-13.576.94--0.00--53.1965.3252.87--148.37--
Stevanato Group SpA1.15bn120.12m5.94bn5.64k43.863.8729.385.190.44730.44734.265.070.52842.752.66203,340.605.54--7.39--29.20--10.48--1.2148.530.2148--10.34--1.95------
Lantheus Holdings Inc1.50bn427.61m6.07bn834.0014.515.1512.394.066.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Merit Medical Systems Inc1.33bn120.04m6.12bn6.95k51.454.6228.114.622.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Glaukos Corp360.35m-149.57m7.77bn907.00--11.61--21.55-2.96-2.967.0612.130.38431.697.53397,295.50-15.95-8.73-17.23-9.3576.6174.77-41.51-28.694.71-311.240.1591--11.2611.66-35.75--14.44--
Repligen Corp622.64m-17.13m7.94bn1.78k--3.94154.7212.75-0.3079-0.307911.0936.000.2331.575.29349,206.40-0.64114.38-0.70325.0350.3755.43-2.7515.918.76--0.20550.00-20.3126.91-77.6420.1324.99--
Bruker Corp3.24bn304.90m8.52bn9.71k27.114.7218.052.632.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Teleflex Inc3.03bn238.01m8.85bn14.50k37.801.9817.532.935.045.0364.0196.500.4042.116.76208,677.503.185.863.466.4255.9954.437.8714.621.396.610.281815.846.573.97-1.4712.732.510.00
Masimo Corp2.04bn78.60m9.05bn3.80k116.326.1852.254.431.451.4537.7227.350.67151.775.52537,526.302.588.653.2310.3150.0557.303.8512.031.112.840.34560.000.604219.00-43.21-15.9631.06--
Bio Rad Laboratories Inc2.58bn-778.69m9.16bn8.03k--1.22--3.55-27.32-27.3290.77267.460.22941.495.61321,321.20-6.929.08-7.269.6054.4355.55-30.1841.974.520.26120.13830.00-4.673.1382.43--3.83--
Henry Schein, Inc.12.50bn314.00m9.20bn25.00k30.212.6415.540.73592.442.4496.8927.991.224.777.73499,960.002.976.094.8610.4431.5930.042.424.400.8176.230.3480.00-2.445.55-22.68-0.145621.27--
Penumbra Inc1.16bn34.55m9.23bn4.20k279.568.35151.567.930.86020.860229.7128.780.78971.046.08277,089.502.342.322.612.6165.7063.902.973.173.25--0.02180.0024.9518.934,643.1668.609.64--
Data as of Nov 22 2024. Currency figures normalised to Repligen Corp's reporting currency: US Dollar USD

Institutional shareholders

45.31%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 20246.32m11.29%
The Vanguard Group, Inc.as of 30 Sep 20244.96m8.87%
BlackRock Fund Advisorsas of 30 Sep 20244.79m8.55%
SSgA Funds Management, Inc.as of 30 Sep 20241.62m2.90%
BlackRock Advisors LLCas of 30 Sep 20241.45m2.60%
Champlain Investment Partners LLCas of 30 Sep 20241.42m2.54%
Sands Capital Management LLCas of 30 Sep 20241.42m2.53%
Macquarie Investment Management Business Trustas of 30 Sep 20241.20m2.15%
Brown Capital Management LLCas of 30 Sep 20241.12m2.00%
Impax Asset Management Ltd.as of 30 Sep 20241.06m1.89%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.